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Introduction: Previous studies have identified cholesterol as an important regulator of breast cancer development.
High-density lipoprotein (HDL) and its cellular receptor, the scavenger receptor class B type I (SR-BI) have both been
implicated in the regulation of cellular cholesterol homeostasis, but their functions in cancer remain to be
established.
Methods: In the present study, we have examined the role of HDL and SR-BI in the regulation of cellular signaling
pathways in breast cancer cell lines and in the development of tumor in a mouse xenograft model.
Results: Our data show that HDL is capable of stimulating migration and can activate signal transduction pathways
in the two human breast cancer cell lines, MDA-MB-231 and MCF7. Furthermore, we also show that knockdown of
the HDL receptor, SR-BI, attenuates HDL-induced activation of the phosphatidylinositol 3-kinase (PI3K)/protein
Kinase B (Akt) pathway in both cell lines. Additional investigations show that inhibition of the PI3K pathway, but not
that of the mitogen-activated protein kinase (MAPK) pathway, could lead to a reduction in cellular proliferation in
the absence of SR-BI. Importantly, whereas the knockdown of SR-BI led to decreased proliferation and migration
in vitro, it also led to a significant reduction in tumor growth in vivo. Most important, we also show that
pharmacological inhibition of SR-BI can attenuate signaling and lead to decreased cellular proliferation in vitro.
Taken together, our data indicate that both cholesteryl ester entry via HDL-SR-BI and Akt signaling play an essential
role in the regulation of cellular proliferation and migration, and, eventually, tumor growth.
Conclusions: These results identify SR-BI as a potential target for the treatment of breast cancer.Introduction
Breast cancer is estimated to have affected >200,000
women in the United States in 2012 and will be responsible
for approximately 40,000 deaths, making it the second
leading cause of cancer deaths [1]. Recently, attention has
focused on examining the role of components of the diet,
such as cholesterol, in breast cancer development. Plasma
cholesterol levels are often lower in patients with advanced
lung [2] and breast cancers [3-5], a phenomenon known as
the “preclinical effect of cancer” [6]. This effect is believed* Correspondence: Philippe.Frank@jefferson.edu
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reproduction in any medium, provided the orto be consequential and not causal [6] but does suggest
a role for cholesterol in cancer. Several epidemiologic
studies have shown a positive correlation between elevated
high-density lipoprotein cholesterol (HDL-C) levels and
breast cancer risk [5,7-9], and recent data have corrobo-
rated this claim [10-16]. In vivo works have suggested that
hypercholesterolemia induced by diet and/or genetic back-
ground leads to increased tumor burden and metastasis
in murine breast cancer models [10,12]. In vitro analyses
have shown that human breast cancer cell lines exhibit
increased proliferation and migration in the presence of
HDL [11,13,15-17]. The effect of cholesterol on breast
cancer may be attributed to several of its properties
and functions. Cholesterol is the precursor of bioactive
steroid hormones such as estrogen. It is also necessary for
the formation of plasma membrane microdomains knownLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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naling molecules in the plasma membrane and, as a re-
sult, have been implicated in the development of
human cancers [19]. Therefore, cholesterol may play
an essential role in the regulation of tumor growth
[20,21].
The HDL lipoprotein is an important carrier of plasma
cholesterol and can function as a signaling molecule by
initiating MAPK and AKTsignaling pathways and stimulate
migration in endothelial cells [22-24]. The activation of
these signaling pathways is dependent on HDL binding to
the HDL receptor, the scavenger receptor class B, type I
(SR-BI), and subsequent lipid transfer to the cell [25-27].
SR-BI functions as the HDL receptor and has been shown
to mediate the selective transfer of cholesteryl ester
from HDL molecules to cells in a process known as the
selective HDL-cholesteryl ester uptake [28]. Its role in the
development of atherosclerosis has been well documented
[28], but its role in cancer has not been extensively investi-
gated. Nevertheless, SR-BI has been implicated in prostate
[29] and breast cancer [15,30]. In the case of breast cancer,
SR-BI protein levels were found to be increased in malig-
nant tissue samples compared with the normal surrounding
tissue [30].
In the present study, we have examined the role of HDL
and SR-BI in the regulation of cellular signaling pathways
in breast cancer cell lines and in the development of tu-
mors in a mouse xenograft model. Our data show that
HDL can stimulate migration and can activate signal-
transduction pathways in the two human breast cancer
cell lines, MDA-MB-231 and MCF7. Furthermore, we
also show that knockdown of the HDL receptor, SR-BI, at-
tenuates HDL-induced activation of the MAPK and
PI3K/Akt pathways in both cells lines. A more detailed
analysis reveals that SR-BI regulates signaling pathways
via Akt activation, and the regulation of SR-BI expression
or activity can limit tumor development in a mouse model.
Methods
Materials
The following antibodies were used: SR-BI was from Novus
Biologicals, Inc. (Littleton, CO, USA). CD31 antibody was
from Abcam, Inc. (Cambridge, MA, USA). Phospho-Erk1/2
(T202/Y204), Erk1/2, Phospho-Akt (S473), and Akt were
from Cell Signaling Technology, Inc. (Beverly, MA, USA).
GAPDH was from Fitzgerald Industries International
(Acton, MA, USA), and β-Actin was from Sigma-Aldrich
Corp. (St. Louis, MO, USA). Anti-mouse secondary anti-
body was from Thermo Fisher Scientific, Inc. (Rockford, IL,
USA), and anti-rabbit secondary antibody was from BD
Biosciences (San Jose, CA, USA). The signaling inhibitors
U0126 and LY294002 were from Cell Signaling Technology
and Sigma-Aldrich, respectively. BLT-1 was from EMD
Millipore (Billerica, MA, USA).Cell culture
MCF7 cells were obtained from the American Type
Culture Collection (ATCC) (Manassas, VA, USA), and
MDA-MB-231 cells were as previously described [31].
MDA-MB-231 and MCF7 cells were grown in Dulbecco
modified Eagle media (DMEM) containing 10% fetal bovine
serum (FBS) in an incubator kept at 37°C with 5% CO2.
Purification of lipoproteins
Human plasma was obtained from adult female volunteers.
Approval for the use of human plasma was obtained
from the Office of Human Research at Thomas Jefferson
University, and consent was obtained from the volunteers
for the use of their plasma samples. Lipoproteins (LDL
(1.019-1.063 g/ml), HDL2 (1.063 to 1.125 g/ml), HDL3
(1.125 to 1.21 g/ml] were separated by density-gradient
ultracentrifugation, as previously described [32]. HDL3
was dialyzed against PBS, 0.5 mM EDTA, 1% NaN3. In
experiments with MCF7 cells, lipoproteins were stripped of
estrogens with activated charcoal to remove endogenous
steroid hormones, as previously described [16].
Migration and invasion assays
Migration was assayed by using modified, noncoated
Boyden chambers from BD Biosciences (San Jose, CA,
USA). Both MDA-MB-231 and MCF7 cells were cultured
in 10-cm dishes in DMEM containing 10% FBS. Cells
were harvested, counted, and washed 3 times with PBS.
Cells were resuspended in DMEM containing 1% BSA,
and 5.0 × 104 cells were added to the upper chambers.
The bottom chambers contained 1% FBS or 100 μg/ml
lipoprotein in 1% BSA. Cells were incubated at 37°C
overnight. At the end of the experiment, upper chambers
were swabbed with a cotton swab to remove nonmigrating
cells, stained with crystal violet, and quantified by using
phase-contrast microscopy. Migration was quantified by
counting the number of cells in five separate fields at
10× magnification. Invasion assays were performed as
described earlier for transwell-migration assays, but
used Matrigel-coated Boyden chambers (BD Biosciences).
The upper chambers contained cells in 1% BSA, and
the bottom chambers contained 1% FBS or 100 μg/ml
lipoprotein in 1% BSA.
Immunoblot analysis
Cells were lysed in radioimmunoprecipitation assay (RIPA)
buffer containing protease and phosphatase inhibitors
from Roche Applied Science (Indianapolis, IN, USA) and
Sigma-Aldrich Corp., respectively, and prepared and
analyzed as previously described [33]. In brief, proteins
were separated by sodium dodecylsulfate/polyacrylamide
gel electrophoresis (SDS-PAGE) and transferred to a
nitrocellulose membrane. Membranes were blocked in 5%
BSA in Tris-buffered saline containing 0.1% Tween-20
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TBS-T and incubated for either 1 hour at room
temperature or overnight at 4°C. Membranes were
washed 3 times in TBS-T, and incubated with horseradish
peroxidase-conjugated secondary antibody for 1 hour at
room temperature. Membranes were washed 3 times in
TBS-T, and visualized by using Pierce Chemiluminescent
Substrate from Thermo Fisher Scientific, Inc.
Knockdown of SR-BI
MDA-MB-231 and MCF7 stably transfected cell lines were
produced by lentiviral transduction. Lentiviral particles
containing a pool of three short-hairpin RNA (shRNA)
constructs targeted against SR-BI were purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
Control lentiviral particles containing scrambled shRNA
sequences were also purchased from Santa Cruz. Cells
were transduced with the lentiviral particles according
to manufacturer’s protocol. Two days after transduction,
target cells containing either control shRNA (shCTL) or
shRNA against SR-BI (shSRBI) were selected by using
2.5 μg/ml puromycin. Successful knockdown was verified
by immunoblot analysis.
Cholesterol-content determination
Cells were grown to confluence in 10-cm dishes in the
presence of complete media (DMEM, 10% FBS). In half
of the plates, cholesterol was extracted with isopropanol.
The extract was dried down in glass tubes under nitrogen
and resolubilized in a smaller volume of isopropanol.
Cholesterol content was determined by using the Choles-
terol E kit from Wako Chemicals USA, Inc. (Richmond,
VA, USA) as per the manufacturer’s instructions. In the
other plates, cells were lysed with 0.5 NaOH, and lysates
were collected. Protein concentration was determined
with the bicinchoninic acid assay (BCA) from Thermo
Fisher Scientific, as per the manufacturer’s instruction.
Total cellular cholesterol levels were calculated by dividing
the total cholesterol by the total protein per dish.
3H-Thymidine incorporation proliferation assays
Cell proliferation was measured with [3H]-thymidine in-
corporation to assess DNA synthesis and proliferation.
MDA-MB-231 cells were seeded (5.0 × 104 cells/well)
in 12-well plates in 1 ml of DMEM containing 10%
fetal bovine serum (FBS) and grown overnight. The fol-
lowing day, media was aspirated, cells were washed
twice with PBS, and were serum-starved with 1% fatty
acid free bovine serum albumin (BSA) for 1 hour.
Media containing FBS, 1% BSA, or 1% BSA with lipo-
proteins (100 μg/ml) and 1 μCi/ml of 3H-thymidine from
Perkin Elmer (Waltham, MA, USA) was added to cells.
Cells were incubated for 6 hours, at which time media
was removed, cells were washed twice with PBS andincubated in 10% trichloroacetic acid to precipitate
DNA. Cells were solubilized in 0.1 M NaOH and 1%
SDS. Radioactivity was measured by liquid scintillation
counting. Protein concentration was determined by
using the BCA assay.
Tumor studies
All mice were housed and maintained in a barrier facility at
the Kimmel Cancer Center at Thomas Jefferson University.
Mice used in this study were athymic nude mice obtained
from Taconic (Hudson, NY, USA). Animal protocols used
for these studies were approved by the Institutional Animal
Care and Use Committee of Thomas Jefferson University.
MDA-MB-231 (106) cells containing either shRNA targeted
against SR-BI (shSRBI) or control shRNA containing
scrambled shRNA (shCTL) were subcutaneously injected
in the flanks of 7- to 9-week-old nude mice. MCF7 cells
(5 × 106) were orthotopically injected into the mammary
fat pad of 9-week-old athymic nude mice implanted with
slow-release 17β-estradiol pellets (0.36 mg/pellet, 60 days)
from Innovative Research of America (Sarasota, FL, USA).
Four weeks after injection, tumors were excised, weighed,
and the volume was determined by using the formula
(width2 × length)/2. Half of each tumor was flash frozen
and stored at −80°C and subsequently homogenized and
lysed in RIPA buffer for immunoblot analysis, as previ-
ously described [33]. The other half was fixed in formalin
for 24 hours and then used to prepare paraffin-embedded
sections.
Immunohistochemical analysis
Paraffin-embedded tumor sections were deparaffinized in
xylene and rehydrated. Antigen retrieval was performed
in 10 mM citrate buffer pH6 for 10 minutes by using a
pressure cooker. Endogenous peroxidase activity was
blocked with 3% H2O2, and sections were blocked in
10% goat serum obtained from Vector Laboratories, Inc.
(Burlingame, CA) and incubated with primary antibody
overnight at 4°C. Sections were washed 3 times with PBS,
incubated with biotinylated secondary antibody for 30
minutes, followed by HRP-conjugated streptavidin for
30 minutes by using a Streptavidin-HRP kit from Dako
North America, Inc. (Carpinteria, CA, USA). After three
washes in PBS, the presence of bound antibody was visual-
ized by using 3,3′-diaminobenzidine (DAB). Slides were
counterstained with hematoxylin, dehydrated, and mounted
with coverslips.
TUNEL assay
Apoptosis was measured with TUNEL assay by using
the TUNEL-based ApopTag Peroxidase In Situ Apoptosis
Detection Kit from Millipore (Temecula, CA, USA),
as per manufacturer’s instructions. In brief, paraffin-
embedded tumor sections were de-paraffinized and
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ase K from Roche Applied Science (Indianapolis, IN,
USA) for 15 min at room temperature and washed, and
peroxidase activity was blocked by incubation in 3%
hydrogen peroxide for 5 minutes. Sections were then in-
cubated with equilibration buffer, followed by incubation
in TdT enzyme for 1 hour at 37°C. After washing, sections
were incubated with HRP-conjugated antibody directed
again digoxigenin for 30 minutes at RT, washed, and
apoptotic positive cells were visualized by using DAB. The
percentage of apoptotic cells was quantified by dividing
the number of TUNEL-positive cells by the total number
of cells observed in four distinct fields per section.
Statistical analyses
All values are expressed as the mean ± standard deviation
(SD). The Prism 4.0 program (GraphPad Software, Inc.,
San Diego, CA, USA) was used for statistical analysis.
Statistical significance was examined by using the
Student’s t test or ANOVA when appropriate.
Results
HDL3 stimulates migration and activates Akt and Erk1/2
in MCF7 and MDA-MB-231 cells
Previous studies have shown that HDL can induce migra-
tion of endothelial cells [24]. In cancer, tumor cell migration
represents the initial step associated with the development
of metastasis [34]. To examine the effect of HDL on breast
cancer cell migration, we studied the effect of lipoproteins
on the migration of two breast cancer cell lines, MCF7
and MDA-MB-231. Interestingly, we found that when
HDL3 was used as the chemoattractant, it induced mi-
gration of both MCF7 and MDA-MB-231 cells by 3.5-
and 61-fold, respectively, compared with the controls
(CTL) as a chemoattractant (Figure 1A, B). Interestingly,
LDL had no effect on the migration of either MCF7 or
MDA-MB-231 cells (Figure 1A, B). Because lipoproteins,
specifically HDL, can act as signaling molecules in endo-
thelial cells and prostate cancer cells and activate Akt and
MAPK pathways [23,35], we examined their effect on
signaling in MCF7 and MDA-MB-231 cells. However,
HDL3 (100 μg/ml) stimulated the activation of Erk1/2 and
Akt in both MCF7 and MDA-MB-231 cells (Figure 1C).
A modest increase in the phosphorylation of Erk1/2
was observed in MDA-MB-231 cells after 30 minutes
of incubation with HDL3. However, a more-robust and
quicker response was observed in MCF7 cells (Figure 1C).
Additionally, HDL3 rapidly activated Akt in both cell lines,
an effect that was prolonged in MCF7 cells (Figure 1C).
These results indicate that HDL3 can function as a
signaling molecule in these two breast cancer cell lines.
LDL had a modest effect on Akt activation, and no effect
on Erk1/2 activation in either MDA-MB-231 or MCF-7
cells was observed (Figure 1D).Knockdown of the HDL receptor, SR-BI, attenuates
the effects of HDL3 on signaling in MDA-MB-231
and MCF7 cells
In the following experiments, we examined the effect of
downregulating the HDL receptor, SR-BI, on signaling in
MDA-MB-231 andMCF7 cells. As demonstrated in Figure 2,
we were able to successfully downregulate SR-BI in both
MDA-MB-231 cells (Figure 2A) and MCF7 cells (Figure 2B).
Knockdown of SR-BI was achieved by stable transduction of
a pool of lentiviral particles containing shRNA sequences
specific for SR-BI (shSRBI). shCTL cells were created by
stable transduction of lentiviral particles containing a scram-
bled version of the shRNA. Knockdown of SR-BI was
assessed by Western blot analysis. In MDA-MB-231 cells,
SR-BI expression was reduced by 5.3–fold, and in MCF7
cells, SR-BI expression was reduced by fourfold (Figure 2A).
To determine the role of SR-BI on the regulation of
signaling pathways, both shCTL and shSRBI MDA-MB-
231 and MCF7 cells were serum starved overnight and
then incubated in media containing 10% FBS for 30
minutes or 100 μg/ml of HDL3 for 0, 5, 15, and 30 minutes,
as indicated. We found that the activation of Akt was
greatly reduced in the shSRBI cells compared with the
shRNA control cells. Similar results were obtained with
both MDA-MB-231 and MCF7 cell lines in the presence
of FBS (lanes 1 and 6 in Figure 2A and B). Consistent with
the results presented in Figure 1C, HDL3 was able to
stimulate the activation of Akt in both cell lines in a time-
dependent manner. However, activation of Akt in shSRBI
MDA-MB-231 cells was greatly reduced when stimulated
by HDL3 for 15 and 30 minutes (Figure 2A, lanes 9 and
10), compared with the Akt activation observed in shCTL
MDA-MB-231 cells when stimulated by HDL3 for the
same periods (Figure 2A, lanes 4 and 5). Similar results
were obtained in MCF7 cells. In that case, Akt activation
was reduced in the shSRBI MCF7 cells when stimulated by
HDL3 for 15 and 30 minutes (Figure 2B, lanes 9 and 10),
compared with shCTL MCF7 cells stimulated by HDL3 for
the same periods (Figure 2B, lanes 4 and 5).
Finally, Erk1/2 appeared to be constitutively active in
MDA-MB-231 cells (Figure 2A, lanes 1 to 10). However,
almost no change in Erk1/2 activation was detected in
shSRBI MDA-MB-231 cells treated with HDL3 for 30
minutes (Figure 2A, lane 10) compared with shCTL MDA-
MB-231 treated with HDL3 for 30 minutes (Figure 2A, lane
5). This effect was in contrast with observations made with
MCF7 cells (Figure 2B). In shCTL MCF7 cells, HDL3
rapidly stimulated Erk1/2 activation, reaching a peak at
5 minutes (Figure 2B, lane 3) but maintaining a sustained
effect at 30 minutes (Figure 2B, lanes 4 and 5). Activation of
Erk1/2 in shSRBI MCF7 cells followed a similar pattern, but
the intensity of activation was greatly reduced (Figure 2B,
lanes 7–10). These results suggest that downregulation of
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Figure 1 HDL3 induces migration and acts as a signaling molecule in MDA-MB-231 and MCF7 cells. Migration of MCF7 (A) and MDA-MB
-231 (B) cells was induced by HDL3. Migration of MCF7 and MDA-MB-231 cells was increased when HDL3, but not LDL, was used as a chemoattractant
compared with CTL (1% BSA alone) in Boyden Chamber assays. Stained cells were quantified by using phase-contrast microscopy. Columns represent the
mean number of migrated cells; bars represent ± standard deviation (SD) (n = 3). The results obtained with CTL and HDL3 groups are significantly different.
No statistical difference was found between CTL and LDL groups. (A) *P < 0.05, Student's t test. (B) **P < 0.01, versus 1% BSA by Student's t test). Results
shown are representative of three independent experiments. (C). MDA-MB-231 and MCF7 cells were incubated for the indicated amounts of time with 100
μg/ml HDL3. Whole-cell lysates were analyzed by Western blotting for the indicated proteins. The arrow indicates the protein corresponding to phospho-
Akt. Results are representative of three independent experiments. (D) MDA-MB-231 and MCF7 cells were incubated for the indicated amounts of time with
100 μg/ml LDL. Whole-cell lysates were analyzed by Western blotting for the indicated proteins. The arrow indicates the protein corresponding to
phospho-Akt. Results are representative of three independent experiments.
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show that the interaction between HDL and SR-BI regulates
activation of these signaling pathways.
Finally, the effect of LDL was also tested in these cell
lines. Results presented in Figure 2C and 2D demonstrate
that the downregulation of SR-BI in MDA-MB231 and
MCF7 cells had no effect on the regulation of Akt and
Erk1/2 activation by LDL.
Knockdown of the HDL receptor, SR-BI, inhibits
proliferation and migration of MDA-MB-231 cells
We observed decreased signaling in shSRBI MDA-MB-231
cells compared with shCTL MDA-MB-231 cells in the
presence of FBS. Therefore, we used media containing 10%
FBS for the remainder of the experiments described later.
FBS contains large amounts of lipoproteins and provides
suitable ligands for SR-BI. Previous studies have shown that
expression of SR-BI in COS-7 cells significantly increased
cholesterol mass in these cells compared with control
vector-transfected cells [36]. To determine whether cellular
cholesterol homeostasis was affected by the downregulation
of SR-BI, we quantified the cholesterol content of shCTL
and shSRBI MDA-MB-231 cells. Under basal conditions,shCTL MDA-MB-231 cells contained a significantly greater
(1.3-fold increase) (P < 0.01) total cholesterol content com-
pared with shSRBI MDA-MB-231 cells (Figure 3A).
Previous studies have shown that a mutant of SR-BI
inhibits proliferation of the luminal B subtype of human
breast cancer cells, MCF7, in the presence of HDL [30]. Fur-
ther, to investigate the role of SR-BI in a triple-negative
(lacking the estrogen receptor (ER), progesterone receptor
(PR), and Her2) basal B subtype breast cancer cell line, we
determined the effect of knocking down SR-BI on the prolif-
eration of MDA-MB-231 cells. The proliferation of shSRBI
MDA-MB-231 cell was reduced by twofold compared with
the proliferation observed with shCTL MDA-MB-231 cells
(P < 0.01) (Figure 3B). Knockdown of SR-BI also significantly
reduced cellular migration (P < 0.05) by 1.65-fold (Figure 3C).
Finally, a reduction of SR-BI protein levels was associated
with a marginally significant reduction of the ability of
MDA-MB-231 cells to invade (Figure 3D) (P = 0.0517).
Pharmacologic inhibition of SR-BI reduces proliferation
and signal transduction in MDA-MB-231 cells
To elucidate the inhibitory effect of SR-BI ablation






FBS (30 min) + - -- - + - - - -













FBS (30 min) + - -- - + - - - -

























FBS (30 min) + - -- - + - - - -











FBS (30 min) + - -- - + - - - -
- 0 155 30 - 0 155 30
Figure 2 Knockdown of SR-BI attenuates HDL3-induced signal transduction in MDA-MB-231 and MCF7 cells. (A,B) MDA-MB-231 and
MCF7 cells were stably transduced by lentiviruses carrying either shRNA against SR-BI (shSRBI) or control shRNA (shCTL). Cells were incubated
with either 10% FBS for 30 minutes or with 100 μg/ml HDL3 for the indicated times. Whole-cell lysates were analyzed by Western blot for the
indicated proteins. The arrow indicates the protein corresponding to phospho-Akt. GAPDH was used as loading control. (C,D) MDA-MB-231 and
MCF7 cells were stably transduced by lentiviruses carrying either shRNA against SR-BI (shSRBI) or control shRNA (shCTL). Cells were incubated
with either 10% FBS for 30 minutes or with 100 μg/ml LDL for the indicated times. Whole-cell lysates were analyzed by Western blot for the
indicated proteins. The arrow indicates the protein corresponding to phospho-Akt. GAPDH was used as loading control. Note that, in panel C, the
image was spliced (between lines 5 and 6) to eliminate an irrelevant line.
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pharmacologic inhibitor of SR-BI, BLT-1 [37]. Previous
work identified BLT-1 as a specific inhibitor of SR-BI
function. BLT-1 has been shown to act by blocking the
transfer of lipids from HDL particles to cells [37]. The
IC50 for this compound was determined to be 50 nM
[37]. The ability of BLT-1 to regulate proliferation was
evaluated in the presence of varying concentrations of this
inhibitor. Accordingly, BLT-1 could inhibit growth of
shCTL MDA-MB-231 cells in a dose-dependent manner(Figure 4A). At doses >50 nM, BLT-1 treatment could sig-
nificantly decrease proliferation of shCTL MDA-MB-231
cells compared with the control untreated cells (P < 0.001
for concentrations of 50 nM, 75 nM, and 100 nM
compared with shCTL MDA-MB-231 incubated with 0
nM BLT-1). Importantly, there was no significant effect
of BLT-1 treatment on the proliferation of shSRBI
MDA-MB-231 cells: Proliferation of shSRBI cells treated
with concentrations of BLT-1 between 0.1 nM and 100





















































































































































Figure 3 Knockdown of the HDL receptor, SR-BI, inhibits proliferation, migration, and invasion of MDA-MB-231 cells. (A) Cholesterol
content of shCTL and shSRBI MDA-MB-231 cells. Cholesterol was extracted from cells with isopropanol, and total cholesterol was measured
enzymatically by using a colorimetric assay. Protein concentration was also determined, and total cellular cholesterol content was expressed as
the amount of cholesterol per milligram of protein. Columns represent the mean cholesterol content, and bars represent ± SD. shCTL
MDA-MB-231 cells display significantly more cholesterol than shSRBI MDA-MB-231 cells (**P < 0.01 by Student's t test). (B) Knockdown of SR-BI
inhibits proliferation of MDA-MB-231 cells. MDA-MB-231 cells containing control shRNA (shCTL) or shSRBI were incubated in the presence of
3H-thymidine for 6 hours in DMEM containing 10% FBS. Proliferation was measured by 3H-thymidine incorporation. Columns represent the mean
3H-thymidine incorporation (cpm/μg protein); bars represent ± (SD). The results obtained for shCTL and shSRBI cells are significantly different
(*P < 0.01 by Student's t test). Results are representative of three independent experiments. (C) Knockdown of SR-BI reduces cellular migration.
Cellular migration of shCTL and shSRBI MDA-MB-231 cells was assessed for 24 hours in a Boyden chamber by using 1% FBS as a chemoattractant.
Columns represent the mean number of migrated cells from three independent experiments, and bars represent ± standard deviation (SD),
(n = 12). The results obtained from the shCTL and shSRBI groups are significantly different (*P < 0.05 versus shCTL, as determined with Student's
t test). (D) Knockdown of SR-BI leads to a marginally significant reduction in cellular invasion. Invasion of shCTL and shSRBI MDA-MB-231 cells was
assessed by Matrigel-coated Boyden chamber assays by using 1% FBS as a chemoattractant. Columns represent the mean number of invaded
cells from three separate experiments (n = 12); bars represent ± SD (P = 0.0517, Student's t test).
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untreated shSRBI MDA-MB-231 cells and shSRBI MDA-
MB-231 cells treated with 100 nM BLT-1 was also
detected. This observation may be due to the presence of
some residual SR-BI protein. Interestingly, no significant
difference was found between shCTL MDA-MB-231 cells
treated with BLT-1 at doses >20 nM and vehicle-treated
(0 nM) shSRBI MDA-MB-231 cells. Taken together, these
results suggest that downregulation or pharmacologic
inhibition of SR-BI has similar effects on MDA-MB-231
proliferation.
We also examined the effect of BLT-1 on signal transduc-
tion in these cells. In agreement with the finding described
in Figure 2A, Akt activation in shSRBI MDA-MB-231 cells
treated with FBS for 30 minutes was reduced compared
with shCTL MDA-MB-231 cells (Figure 4B). Similar results
were obtained with shCTL MDA-MB-231 cells with treated
BLT-1. Akt activation was reduced in the treated shCTL
MDA-MB-231 cells compared with untreated control cells.
Finally, SR-BI knockdown or pharmacologic inhibition hadno effect on Erk1/2 activation (Figure 4B) compared with
the control cells. Collectively, these data suggest that Akt
activation may be mediated, in part, by SR-BI, and the
downregulation of SR-BI is responsible for the observed re-
duction in the cellular proliferation.
Inhibition of PI3K, not MEK1/2, inhibits growth of shCTL
MDA-MB-231 cells
To elucidate the mechanism by which SR-BI knockdown
inhibits proliferation, we used pharmacologic agents
to inhibit PI3K and MAPK signaling pathways. We show
that the PI3K inhibitor, LY294002, abolished FBS-induced
activation of Akt (Figure 5A) in shCTL and shSRBI MDA-
MB-231 cells. Importantly, PI3K inhibition significantly
reduced proliferation of shCTL MDA-MB-231 cells to
levels similar to those observed with untreated shSRBI
MDA-MB-231 cells (Figure 5B). In addition, PI3K in-
hibition had no effect on the proliferation of shSRBI
MDA-MB-231 cells, suggesting that downregulation of
























































Figure 4 Inhibition of SR-BI by the small-molecule BLT-1 inhibits proliferation of MDA-MB-231 cells. (A) Pharmacologic inhibition of SR-BI
in MDA-MB-231 cells inhibits cellular proliferation. MDA-MB-231 shCTL cells were incubated in the presence of the indicated doses of BLT-1
and 3H-thymidine added to the culture media for 6 hours. At this time, the assay was stopped, and lysates were collected. Columns represent the
mean 3H-thymidine incorporation (cpm/μg protein); bars represent ± SD. Results obtained with shSRBI MDA-MB-231 CTL (0 nM BLT-1) are
significantly different from those obtained with shCTL 0 nM BLT-1 (CTL) (a, P < 0.001), shCTL 0.1 nM BLT-1 (b, P < 0.001), and shCTL 1.0 nM
(c, P < 0.05). Results obtained with shCTL MDA-MB-231 CTL (0nM BLT-1) were significantly different from those obtained with shCTL 50 nM BLT-1
(d, P < 0.001), shCTL 75 nM BLT-1 (e, P < 0.001), and shCTL 100 nM (f, P < 0.001). Significance was determined by one-way ANOVA with Tukey's
post-test analysis. (B) Pharmacologic inhibition of SR-BI attenuates signaling in MDA-MB-231 cells. Western blot analysis was performed with
extracts obtained from shSRBI MDA-MB-231 cells treated with vehicle, shCTL MDA-MB-231 cells treated with vehicle, and shCTL MDA-MB-231 cells
treated with BLT-1 (50 nM). Cells were serum starved overnight, incubated with vehicle alone or BLT-1 for 3 hours, and then treated with 10% FBS
for 30 minutes.
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activates Erk1/2, did not affect proliferation of shCTL
MDA-MB-231 or shSRBI MDA-MB-231 cells (Figure 5B).
Erk1/2 activation, however, was significantly reduced by
inhibition of MEK1/2 in both cell types (Figure 5A).
These results suggest that the MAPK pathway does not
play a significant role in SR-BI-mediated signaling and
proliferation, unlike the PI3K pathway.Knockdown of SR-BI results in decreases in in vivo tumor
growth of MDA-MB-231 and MCF7 cells
To assess the effect of SR-BI knockdown in vivo, we sub-
cutaneously injected shSRBI and shCTL MDA-MB-231
cells into the flanks of nude mice. Four weeks after
injection, tumors were excised from dead mice, and
mass and volume were measured. Tumors obtained
with shCTL MDA-MB-231 were significantly larger than
those obtained from shSRBI MDA-MB-231: tumor vol-
ume and mass were increased by 3.8-fold and 3.7-fold,
respectively (Figure 6A). To determine the role of SR-BI
in tumor growth in MCF7 cells, shCTL and shSRBI
MCF7 cells (5 × 106) were orthotopically injected into the
mammary fat pad of athymic nude mice after implantation
with slow-release 17β-estradiol pellets. Four weeks after
injection, mice were killed, tumors were excised, and mass
and volume of tumors were determined (Figure 6B).
Tumors obtained with shCTL MCF7 were 1.5-fold larger
than those obtained with shSRBI MCF7 (P < 0.05), and
1.3-fold larger by mass (marginally significant).To elucidate the mechanism by which SR-BI regulates
tumor formation, tissue immunohistochemical analyses
(Figure 6C) and immunoblot analyses of homogenized
tumors (Figure 6D) were performed. Immunohistochemis-
try analyses demonstrated the reduction in SR-BI protein
expression in shSRBI MDA-MB-231-derived tumors
compared with shCTL MDA-MB231. Results also revealed
that levels of the proliferative marker, pErk1/2, were
decreased in shSRBI MDA-MB-231 tumors, compared
with those observed in control tumors. Consistent with
in vitro findings, pAkt levels were decreased in shSRBI
MDA-MB-231 tumors compared with those observed
in control tumors.
Because cholesterol has been shown to play a role in the
regulation of angiogenesis [38], microvessel density in the
tumors was assessed by staining tumor sections for CD31,
a specific marker of endothelial cells (Figure 7A). A signifi-
cant increase in microvessel density was observed with tu-
mors obtained from shCTL MDA-MB-231 cells compared
with those obtained from shSRBI MDA-MB-231 cells.
These data suggest that SR-BI can regulate angiogenesis
in these tumors.
Finally, SR-BI has been shown to activate Akt [23],
which may inhibit apoptosis, thereby promoting cell
survival [39]. Therefore, we assessed apoptosis with
TUNEL staining in tissue sections obtained from shCTL
and shSRBI MDA-MB-231 xenograft tumors (Figure 7B).
As anticipated, we observed a significant increase in apop-













































1        2        3       4        5        6
shCTL shSRBI shCTL shSRBI shCTL shSRBI
LY294002
U0126
- - + + - -












Figure 5 Inhibition of PI3K, not MEK1/2, prevents proliferation of MDA-MB-231 cells. (A) LY294002 and U0126 effectively inhibit Akt and
Erk1/2 activation in MDA-MB-231 cells. Serum-starved shCTL and shSRBI MDA-MB-231 cells were incubated with or without the inhibitors
LY294002 (15 μM) or U0126 (10 μM) for 2 hours. Medium containing 10% FBS was added for 30 minutes, cells were lysed, and whole-cell lysates
were analyzed by Western blot for the indicated proteins. GAPDH was used as a loading control. (B) PI3K inhibition reduces cellular proliferation
of shCTL MDA-MB-231 cells. shCTL and shSRBI MDA-MB-231 cells were incubated with culture media containing either LY294002 (15 μM) or
U0126 (10 μM) and 3H-thymidine for 6 hours, at which time, the assay was stopped, and lysates were collected. Columns represent the mean [3H]
thymidine incorporation (cpm/μg protein); bars represent ± SD. Results obtained from vehicle-treated (CTL) shCTL MDA-MB-231 cells are
significantly different from those obtained with shSRBI MDA-MB-231 cells (**P < 0.001, one-way ANOVA with Tukey's post-test analysis). Results
obtained from vehicle-treated shCTL MDA-MB-231 cells (CTL) are significantly different from those obtained with shCTL MDA-MB-231 cells treated
with LY294002. Note that proliferation of shCTL MDA-MB-231 cells treated with U0126 was not significantly different from that observed with
vehicle-treated shCTL MDA-MB-231 cells. Proliferation of shSRBI MDA-MB-231 cells treated with LY294002 or U0126 was also not significantly
different from that observed with vehicle-treated shCTL MDA-MB-231 cells. Results are representative of three independent experiments.
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In the present study, we examined the role of HDL and its
receptor, SR-BI, in breast cancer development and progres-
sion. We found that HDL3 stimulates migration and acti-
vates signaling pathways such as MAPK and PI3K in two
breast cancer cell lines. Inhibiting selective HDL-cholesteryl
ester uptake by knocking down or pharmacologically
inhibiting SR-BI resulted in an attenuation of cell-signaling
events induced by HDL. Additionally, loss of SR-BI resulted
in decreased proliferation, migration, and tumor growth of
MDA-MB-231 cells. These findings suggest that regulat-
ing cholesterol metabolism and cellular signaling pathways
via SR-BI may be linked and may additionally identify
new targets associated with tumor progression.
HDL, signal transduction, and cellular migration
HDL has a well-established role in the etiology of ath-
erosclerosis, particularly in reverse cholesterol transport,
whereby HDL removes excess cholesterol molecules
from peripheral tissues and returns them to the liver for
excretion or recycling [40]. In addition, HDL functions in
a number of other cellular processes, including inhibition
of apoptosis in macrophages [41], induction of migration
in endothelial cells [24], and the initiation of cell-signaling
events in multiple cell types [22,23,42]. Although clinical
studies have suggested that plasma HDL levels may becorrelated with increased breast cancer risk [5,7-9,12],
the mechanisms by which HDL exerts its effect have yet
to be elucidated. HDL has been shown to activate Erk1/
2 in fibroblasts [23,42], Chinese hamster ovary cells
[22], endothelial cells [23], and prostate cancer cells
[35,43]. Studies have also shown that it can activate Akt in
endothelial [23] and prostate cancer cells [35,43]. Interest-
ingly, the activation of Erk1/2 [44] and Akt [39,45] has
been implicated in several human cancers, including
breast cancer.
In the present study, we established a role for HDL as a
mediator of signal transduction in two breast cancer cell
lines. Consistent with the results obtained in other cell types,
we found that, in both MCF7 and MDA-MB-231 cells, incu-
bation with HDL3 induces a rapid activation of both Erk1/2
and Akt signaling pathways. These novel findings in breast
cancer suggest that HDL may regulate various signaling
pathways and may therefore alter tumor progression.
In the present study, we found that HDL can induce
migration of two breast cancer cell lines, MCF7 and
MDA-MB-231, suggesting that HDL may play a role in the
early stages of metastasis. This finding is consistent with
previous studies showing that HDL can stimulate migration
of endothelial cells [24,46]. Interestingly, the observed
migration was shown to be mediated by SR-BI [24]. By con-
trast, a recent study reported that HDL inhibits migration
A































































































Figure 6 Knockdown of SR-BI inhibits xenograft tumor growth in vivo. (A) Knockdown of SR-BI in MDA-MB-231 cells decreases tumor growth
in vivo. Athymic nude mice were injected with 106 MDA-MB-231 cells carrying control shRNA (shCTL) or shSRBI. Four weeks after injection, mice were
killed, and tumors were excised. Tumors were weighed and volume determined by using the formula (length × width2)/2. Columns represent the mean
volume and mass, respectively; bars represent ±SD. Tumors obtained with shCTL cells were significantly larger by weight and volume than were the
tumors obtained with shSRBI. (*P < 0.05; n = 14 shCTL, n = 13 shSRBI) (B) Knockdown of SR-BI in MCF7 cells decreases tumor growth in vivo. MCF7 cells (5
× 106) were orthotopically injected into the mammary fat pads of 9-week-old athymic nude mice implanted with slow-release 17β-estradiol pellets (0.36
mg/pellet, 60 days). Four weeks after injection, mice were killed, and the tumors were excised. Tumors were weighed and volume determined by using
the formula (length × width2)/2. Columns represent the mean volume and mass, respectively; bars represent ± SD. The shCTL tumors were significantly
larger by volume than were the shSRBI tumors (*P < 0.05; n = 8 shCTL, n = 7 shSRBI). (C) shCTL tumors display increased expression of proliferative markers
compared with shSRBI tumors. Immunohistochemistry was performed to determine expression patterns of SR-BI and pErk1/2 in MDA-MB231 tumors.
(D) The shCTL tumors display increased expression of proliferative markers compared with shSRBI tumors. Three tumors per cell type were analyzed by
Western blot analysis for the indicated proteins. GAPDH was used as a loading control.
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in this study, the investigators used serum as the chemo-
attractant, and HDL was added to the upper chamber,
thereby measuring the ability of HDL to prevent cellular
migration induced by serum. By contrast, our method
allows the analysis of the role of HDL in the regulation of
cellular migration and therefore allows a direct measure-
ment of the capability of HDL to induce migration of
MDA-MB-231 cells. As a result, our results indicate that
HDL may play a role in the pathogenesis of breast cancer,
especially in the later stages.
SR-BI, signal-transduction regulation, and tumor formation
SR-BI has been implicated as a mediator of several cell-
signaling events in the context of atherosclerosis [22,23,25-27].Previous studies have shown that HDL binding to SR-BI
and subsequent lipid transfer are sufficient to activate Src,
which subsequently activates the PI3K/Akt and MAPK
pathways [25,27]. In endothelial cells, one of the down-
stream effectors of Akt is eNOS, which catalyzes the pro-
duction of NO. The results obtained in the present study
are consistent with the hypothesis that SR-BI may also
play a role in signal transduction in the context of cancer.
In agreement with this hypothesis, upon knockdown or
pharmacologic inhibition of SR-BI in MDA-MB-231
cells, Akt activation was significantly reduced, suggesting
that SR-BI may be mediating this response. In addition,
downregulation of SR-BI was accompanied by a reduction
of total cholesterol levels in MDA-MB-231 cells. These




















































Figure 7 Knockdown of SR-BI inhibits xenograft tumor growth in vivo. (A) Knockdown of SR-BI results in decreased angiogenesis in
MDA-MB-231 xenograft tumors. Immunohistochemistry was performed to determine expression of CD31. CD31 staining was quantified by
averaging the number of vessels per field in five separate fields per sample. Columns represent the mean microvessel density; bars represent ± SD.
Microvessel density was statistically greater in shCTL MDA-MB-231 tumors compared with shSRBI MDA-MB-231 cells (*P < 0.05 Student's t test;
n = 4 per group). (B) Knockdown of SR-BI results in increased apoptosis in MDA-MB-231 xenograft tumors. Images shown are representative of TUNEL
assay staining. Percentage of TUNEL-positive cells was calculated by dividing the number of TUNEL-positive cells by the total number of cells in four
separate fields. Columns represent the percentage of TUNEL-positive cells; bars represent ± SD. TUNEL staining is statistically increased in shSRBI
MDA-MB-231 tumors compared with shCTL MDA-MB-231 tumors (***P < 0.001, Student's t test, shCTL n = 3, and shSRBI n = 4).
Danilo et al. Breast Cancer Research 2013, 15:R87 Page 11 of 13
http://breast-cancer-research.com/content/15/5/R87cholesterol flux mediated by SR-BI plays a role in the
regulation of signal-transduction initiation [26]. In our
model, decreased total cholesterol levels may represent a
reduction in SR-BI-mediated cholesterol flux and therefore
significantly reduce signal-transduction activation. SR-BI
also binds LDL, which can, like HDL, promote the cellular
entry of cholesteryl ester. Although LDL, may promote the
entry of cholesteryl ester via SR-BI, it is not sufficient to
induce migration of breast cancer cells, and it does not
appear to alter Akt activation (Figure 2C, D). Taken
together, our data suggest that both cholesteryl ester entry
via HDL-SR-BI and Akt activation are required for cellular
proliferation and migration, and, eventually, tumor growth.
Activation of the PI3K/Akt pathway promotes growth,
survival, and proliferation [45] and has been implicated
in a variety of human cancers [39]. Importantly, Akt is
aberrantly hyperactivated in approximately 40% of breast
cancers [39]. We observed a reduction in proliferation
and migration in the SR-BI-knockdown cells compared
with control cells in association with reduced Akt activa-
tion. These results suggest that SR-BI may mediate the
activation of Akt and its downstream effects in the
presence of HDL. Mechanistically, we showed that the
inhibition of the PI3K/Akt pathway results in significantly
reduced proliferation of shCTL MDA-MB-231 cells, simi-
lar to the reduction in proliferation observed in shSRBI
MDA-MB-231 cells. Importantly, no further reduction inproliferation of shSRBI MDA-MB-231 cells was detected
upon inhibition of the PI3K/Akt pathway. Taken together,
these data suggest that reduced Akt activation observed
in the shSRBI MDA-MB-231 cells may be responsible
for reduced proliferation of these cells compared with
shCTL MDA-MB-231 cells.
Previous studies suggested a role for SR-BI in the etiology
of breast cancer. Cao et al. [30] showed that expression of
SR-BI is increased in human breast tumors compared with
the normal surrounding tissue. They also demonstrated
that recombinant expression of a mutant form of SR-BI,
which lacked the carboxyl-terminal tail of the protein,
could inhibit proliferation of breast cancer cells. Their
study further suggested that this effect was possibly due to
reduced Akt activation. Our study is the first to demon-
strate directly that Akt activation is reduced when SR-BI
is knocked down or pharmacologically inhibited. Further-
more, in agreement with the previously mentioned study
[30], we showed that proliferation of MDA-MB-231 cells
was significantly inhibited by downregulation of SR-BI
protein levels and by pharmacologic inhibition of SR-BI.
In addition, we observed that SR-BI knockdown inhibits
migration. This finding may suggest a role for SR-BI in
the initiation of metastasis. Finally, we demonstrated that
knockdown of SR-BI in MDA-MB-231 cells can lead to
reduced tumor growth in vivo accompanied by increased
activation of Erk1/2 and Akt, and an increase in cellular
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http://breast-cancer-research.com/content/15/5/R87apoptosis. In MCF7 cells, knockdown of SR-BI also led to
reduced xenograft tumor growth.
Previous studies have shown that Akt can inhibit
apoptosis through a variety of mechanisms, including the
phosphorylation of BAD, thus preventing cytochrome c
release from mitochondria and the direct inhibition of the
caspase activation cascade [39]. Increased cellular choles-
terol levels have been shown to increase Akt activation
and decrease apoptosis in prostate cancer cells [47]. Con-
sistent with these observations, a recent study showed that
inhibition of xenograft tumor growth could be achieved
with colon cancer cells that re-express the ATP-binding
cassette transporter A1 (ABCA1) [48]. ABCA1 is a lipid
transporter that mediates the efflux of cellular cholesterol
to lipid-free apolipoprotein A-I [49]. Furthermore, in this
study, re-expression of ABCA1 resulted in decreased
mitochondrial cholesterol content and increased release of
cytochrome c, which ultimately led to increased apoptosis.
Our work also indicated that SR-BI knockdown can sig-
nificantly reduce apoptosis in xenograft tumors, as shown
by TUNEL staining. Consequently, a reduction in the
levels of cellular cholesterol content may be responsible,
at least in part, for the decreased apoptosis observed in
our model. Taken together, these data also suggest an im-
portant role for cholesterol in the regulation of cellular
signaling pathways and tumor formation. Importantly, ex-
cess cellular cholesterol accumulates in the form of esteri-
fied cholesterol. Previous works and ours suggest that the
accumulation of esterified cholesterol may lead to a
modification of signaling pathways associated with
proliferation and migration in tumors. Consistent with
this hypothesis, increasing cellular esterified choles-
terol levels have been shown to induce cellular prolifer-
ation and enhance invasiveness of tumor cell lines [50].
Conversely, the inhibition of cholesterol esterification
has been shown to have the reverse effect [51,52].
Conclusions
In summary, our results suggest that HDL and SR-BI have
pro-oncogenic activity and can induce migration and acti-
vate signal-transduction pathways responsible for cellular
proliferation and tumor formation in two breast cancer
cell lines. Additionally, knockdown or pharmacologic
inhibition of SR-BI could attenuate signaling mediated
by HDL and inhibit proliferation, migration, and tumor
growth. Taken together, these findings identify SR-BI and
HDL as potential therapeutic targets for the treatment of
breast cancer.
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